Clever Leaves Exports Its First Commercial Shipment of THC Flower to the United States to Biopharmaceutical Research Company

NEW YORK: Clever Leaves Holdings Inc., a leading multinational operator and licensed producer of pharmaceutical-grade cannabinoids, announced today the exportation of 30 kg of high-THC cannabis flower from its Portugal facility to Biopharmaceutical Research Company (“BRC”), a DEA-licensed pharmaceutical company that develops federally compliant active pharmaceutical ingredients (API) for plant-based therapeutics in the United States. Not only does this fortify Clever Leaves’ entrance into the U.S. and solidify BRC’s ability to transact internationally, but it positions the two organizations as some of the first companies ever to commercially ship dried cannabis flower from Portugal to the U.S.

Under the agreement, Clever Leaves’ product, which meets strict pharmaceutical standards, will be used for BRC’s pharmaceutical development projects. In addition to this shipment of dried cannabis flower, BRC and Clever Leaves have built a strong partnership over the past year through their collaboration in Project Change Lives, an initiative announced earlier this year to contribute up to USD$25M in medical cannabis products to help advance scientific research in the U.S.

“Exporting THC flower to BRC, a DEA-licensed company located in the U.S., not only represents an important commercial milestone for Clever Leaves, but it demonstrates our capabilities to determine and execute upon a viable regulatory pathway to enter the U.S., the largest cannabis market in the world,” said Kyle Detwiler, CEO of Clever Leaves. “By becoming one of the first companies to commercially export THC flower to the U.S., we are paving Clever Leaves’ path into the U.S. medical cannabis industry through a partner such as BRC. We are honored to provide BRC the high-quality product they need to advance in their research, development, and production.”

“Our partnership with Clever Leaves continues to yield exciting research opportunities that will one day make a difference in the lives of patients,” said George Hodgin, CEO of Biopharmaceutical Research Company. “Both companies share the same values when it comes to DEA compliance—we take it seriously—which is why we believe this partnership is only getting started. We are thrilled to partner with Clever Leaves once again and are eager to begin working with this premium quality product.”

Clever Leaves’ Portuguese cultivation facility is located on approximately 9 million square feet of land and consists of approximately 110,000 square feet of high technology greenhouse facilities with expansion to approximately 270,000 square feet nearly complete. The facility was granted a license from INFARMED I.P., the Portuguese regulatory authority with oversight over the pharmaceutical industry in Portugal, for importing, exporting, and cultivating cannabis. Our state-of-the-art sophisticated facilities in Portugal, which are Good Agricultural and Collecting Practice (GACP) certified, are currently operational and commercially active, with successful exports to various countries, including Australia.

Biopharmaceutical Research Company Will Be Among First in the Nation to Receive a License for Federal Cannabis Production 

CALIFORNIA: Biopharmaceutical Research Company (BRC), a specialty pharmaceutical manufacturing and analytical company focused on plant-based therapeutics, will soon be awarded one of the first federal production licenses from the Drug Enforcement Administration (DEA) to produce clean, consistent and compliant cannabis for federally approved researchers across the United States.

BRC will be among a select few organizations to receive such a license after the DEA amended regulations within the Controlled Substances Act to begin allowing the cultivation of cannabis for research purposes. Prior to today’s decision by the DEA, only one facility in the United States was federally authorized to cultivate cannabis for research purposes.

“Once finalized, this federal license will forever change the trajectory of our business and the medicinal cannabis industry. The DEA’s leadership will set off a nationwide wave of innovative cannabis-derived treatments, unlock valuable intellectual property and create high quality American jobs,” said BRC CEO George Hodgin, a former US Navy SEAL.

“The BRC team is already familiar with DEA compliance procedures based on our extensive history of controlled substances activity, and our world class staff is ready to hit the ground running on this new business arm that the DEA has authorized. Cultivation and compliance are our bread and butter, and now that we are in a position to receive this license, our best work yet can begin to take shape.”

BRC is already certified by the DEA and United States Department of Agriculture (USDA) to analyze and test controlled substances, including cannabis and hemp.

“We have invested a great deal of money and waited a very long time for this over the last four years, and this is the validation and the holy grail we’ve been waiting for,” added Hodgin. “With this license, BRC can legally produce quality cannabis and cannabis-derived products that can be used to identify new treatments that can help veterans and all patients struggling with chronic pain, cancer, and countless other illnesses. Equally important, we will also gain valuable insights into the potential dangers and misuse associated with cannabis that will help keep all Americans safe and healthy. We are proud and honored to be one of the first federally legal cannabis companies in the United States.”